Toddlers' choice: Yo-Yoing diabetes control or deci-unit insulin dosing?

Sarah Aa Abul-Ainine1, Ahmad Aa Abul-Ainine

  • 1Sarah AA Abul-Ainine, Foundation Year Doctor Royal Bolton Hospital, Bolton, BL4 0JR, England, United Kingdom.

Insights

The withdrawal of weak insulin mixtures for toddlers with diabetes necessitates new solutions. Deci-unit insulin pens offer an affordable, accurate alternative to insulin pumps, improving glycemic control and child-friendly diabetes management.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Diabetes Management

Background:

  • Rising incidence of type 1 diabetes in toddlers.
  • Withdrawal of traditional weak insulin mixtures (WIM) for pediatric use.
  • Challenges with current insulin delivery methods for young children, including insulin pumps and multi-dose insulin regimens (MuDIR).

Purpose of the Study:

  • To highlight the difficulties in managing toddlers' diabetes after the withdrawal of WIM.
  • To propose a simple, affordable solution for precise insulin dosing in young children.
  • To evaluate the potential of deci-unit insulin pens as an alternative to insulin pumps.

Main Methods:

  • Analysis of current insulin delivery challenges for toddlers (insulin pumps, MuDIR, insulin mixing, dilution).
  • Evaluation of dosing accuracy and variability with half-unit insulin pens.
  • Introduction and assessment of deci-unit insulin pens (U20 insulin) for pediatric diabetes care.

Main Results:

  • Half-unit insulin pens provide inaccurate dosing increments (25%-100%) for toddlers' erratic needs.
  • Insulin pumps, while effective, are not universally accessible or affordable.
  • Deci-unit insulin pens allow for precise 5%-20% dose adjustments, reduce variability from dribbling, and offer an affordable alternative.

Conclusions:

  • Current insulin delivery methods pose significant challenges for toddlers with diabetes.
  • Deci-unit insulin pens provide a more accurate and accessible option for pediatric diabetes management.
  • This innovation can improve glycemic control, reduce maternal anxiety, and uphold children's rights to safe and effective treatment.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...